fda drug safety communication semaglutide naion 2025 linked to increased risk of vision loss in diabetes patients fda safety communication semaglutide vision

Key ingredient Hydroxypinacolone Retinoate, a next-generation retinoid, supports skin turnover for smoother texture and refined tone

2025, Grosman, Yacov, and Leonid Kalichman

BPC-157, ipamorelin, and similar peptides arent FDA-approved for any indication, and clinical evidence is limited compared to GLP-1 medications

DXA is used to establish or confirm a diagnosis of osteoporosis, to help predict future fracture risk, and to monitor patients over time, particularly those undergoing osteoporosis treatment

Precision is our language

Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK